| A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy D Kanagavel, IA Pokataev, MY Fedyanin, AA Tryakin, IS Bazin, ... Annals of oncology 21 (9), 1779-1785, 2010 | 76 | 2010 |
| A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer HKM Vollan, OM Rueda, SF Chin, C Curtis, G Turashvili, S Shah, ... Molecular oncology 9 (1), 115-127, 2015 | 53 | 2015 |
| Epstein–Barr virus-associated gastric cancer: disease that requires special approach E Ignatova, D Seriak, M Fedyanin, A Tryakin, I Pokataev, S Menshikova, ... Gastric Cancer 23, 951-960, 2020 | 39 | 2020 |
| Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical … I Pokataev, M Fedyanin, E Polyanskaya, A Popova, J Agafonova, ... ESMO open 5 (1), e000578, 2020 | 38 | 2020 |
| Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes M Emelyanova, E Pudova, D Khomich, G Krasnov, A Popova, I Abramov, ... Therapeutic Advances in Medical Oncology 14, 17588359221083050, 2022 | 16 | 2022 |
| Prognostic factors and efficacy of different chemotherapeutic regimens in patients with mediastinal nonseminomatous germ cell tumors M Fedyanin, A Tryakin, Y Mosyakova, I Pokataev, A Bulanov, T Zakharova, ... Journal of cancer research and clinical oncology 140, 311-318, 2014 | 14 | 2014 |
| Practical recommendations for drug treatment of pancreatic cancer IA Pokataev, SB Alieva, OA Gladkov, VE Zagainov, NE Kudashkin, ... Malignant Tumoursis 7 (3-S2), 367, 2017 | 9 | 2017 |
| Microsatellite instability as a unique characteristic of tumors and a predictor of response to immune therapy AA Tryakin, MY Fedyanin, AS Tsukanov, YA Shelygin, IA Pokataev, ... Malignant tumours 9 (4), 59-69, 2020 | 8 | 2020 |
| Olanzapine (OLN) versus aprepitant (APR) in patients receiving high-emetogenic chemotherapy: Final results of randomized phase II trial. A Rumyantsev, E Glazkova, R Nasyrova, E Ignatova, L Chitia, A Popova, ... Journal of Clinical Oncology 37 (15_suppl), 11504-11504, 2019 | 8 | 2019 |
| Primary systemic therapy with metronomic doxorubicin, cyclophosphamide, and capecitabine in locally advanced and metastatic triple-negative breast cancer. M Skrypnikova, M Frolova, E Ignatova, I Pokataev, M Stenina, S Tjulandin Journal of Clinical Oncology 29 (15_suppl), 1110-1110, 2011 | 8 | 2011 |
| Maintenance therapy following first-line chemotherapy in metastatic colorectal cancer: toxicity and efficacy—single-institution experience M Fedyanin, A Tryakin, A Vybarava, D Chekini, I Pokataev, O Sekhina, ... Medical Oncology 32 (1), 429, 2015 | 7 | 2015 |
| Prakticheskie rekomendatsii po lekarstvennomu lecheniyu raka yaichnikov/pervichnogo raka bryushiny/raka matochnykh trub SA Tyulyandin, NV Den'gina, LA Kolomiets, NVM Morkhov KYu, ... Zlokachestvennye opukholi 4, 123-34, 2016 | 5 | 2016 |
| Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical … I Pokataev, M Fedyanin, E Polyanskaya, A Popova, J Agafonova, ... | 5 | |
| A phase II nonrandomized study of oxaliplatin/doxorubicin combination therapy in the treatment of recurrent ovarian cancer I Pokataev, A Tryakin, A Tjulandina, M Fedyanin, S Tjulandin Clinical Ovarian and Other Gynecologic Cancer 6 (1-2), 11-16, 2013 | 4 | 2013 |
| Gut microbiome as a predictor of the anti-PD-1 therapy success: metagenomic data analysis DE Fedorov, AV Pavlenko, EI Olekhnovich, KM Klimina, IA Pokataev, ... Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry 15 (2), 161-165, 2021 | 3 | 2021 |
| Intestinal microbiome as a predictor of the anti-PD-1 therapy success: metagenomic data analysis DE Fedorov, EI Olekhnovich, AV Pavlenko, KM Klimina, IA Pokataev, ... Biomeditsinskaia Khimiia 66 (6), 502-507, 2020 | 3 | 2020 |
| 466P FOLFOXIRI versus FOLFOX or FOLFIRI with targeted therapy in patients with mutant BRAF metastatic colorectal cancer: A systematic review and meta-analysis M Fedyanin, E Polyanskaya, H Elsnukaeva, A Tryakin, I Pokataev, ... Annals of Oncology 31, S439-S440, 2020 | 3 | 2020 |
| Intratumoral Heterogeneity of SMAD4 Immunohistochemical Expression and Its Role in Prediction of Recurrence Pattern in Patients with Resectable Pancreatic Cancer I Pokataev, A Kudaibergenova, A Artemyeva, A Popova, A Rumyantsev, ... Journal of Gastrointestinal Cancer 50, 478-484, 2019 | 3 | 2019 |
| Surgical quality issues in ovarian cancer patients AA Rumyantsev, IA Pokataev, AS Tjulandina, SA Tjulandin Malignant tumours 8 (1), 31-37, 2018 | 3 | 2018 |
| 1881O Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study N Agarwal, J Brugarolas, P Ghatalia, S George, J Haanen, HP Gurney, ... Annals of Oncology 34, S1011, 2023 | 2 | 2023 |
